Rajeev Sharma :- Russia has announced a major scientific breakthrough in the fight against the deadly Ebola virus, claiming to have developed an effective vaccine targeting a newly emerging strain linked to the latest outbreak in Central Africa.
Russian Health Minister Mikhail Murashko confirmed the development of the vaccine, describing it as a significant advancement in global efforts to contain the rapidly spreading infection. The vaccine has reportedly been designed to combat the rare “Bundibugyo” strain of Ebola, for which no approved vaccine or specialised treatment had previously been available.
According to information released by the Russian Embassy in South Africa, the newly developed vaccine is expected to play a crucial role in addressing the growing health emergency in the Democratic Republic of Congo (DRC), where the virus has been spreading at an alarming pace.
The World Health Organization (WHO) has already expressed serious concern over the outbreak. Health authorities have reported more than 900 suspected cases in Congo so far, while at least 220 suspected deaths have been recorded. Among them, 10 fatalities have been officially confirmed as Ebola-related. The virus has also crossed borders into neighbouring Uganda, where five confirmed cases have emerged.
Ebola is regarded as one of the world’s most dangerous infectious diseases. The virus is believed to spread initially from wild animals such as bats and primates to humans before transmitting further through direct contact with infected blood or bodily fluids. Past outbreaks have shown fatality rates ranging between 25 and 90 per cent, with an average mortality rate close to 50 per cent.
Earlier this month, the WHO declared the outbreak a “Public Health Emergency of International Concern,” underlining the seriousness of the situation and the potential risk of international spread.
Medical experts believe Russia’s latest vaccine development could provide a much-needed ray of hope for countries struggling to contain the outbreak, particularly in regions with limited healthcare infrastructure and rising infection rates.
